Company news
Botanix Pharmaceuticals Limited (ASX:BOT) news
Botanix Pharmaceuticals Limited news releases on 6ix. Latest, Jul 3, 2017: Botanix Completes Successful Phase 1 BTX 1503 Clinical Study
Press releases — page 4
Botanix Completes Successful Phase 1 BTX 1503 Clinical Study
July 3, 2017
12 Month Operational Review Highlights Significant Progress
June 26, 2017
Successful Pilot Study for BTX 1701 Facial Cleanser
June 7, 2017
Completion of Tranche 2 of Capital Raising Placement
May 19, 2017
Botanix Commences First Clinical Study for BTX 1503
May 7, 2017
Completion of the Tranche 1 Placement
April 12, 2017
Reinstatement to official quotation
April 4, 2017
Suspension from Official Quotation
April 3, 2017
Botanix Receives Approval for Synthetic Cannabidiol Trial
March 29, 2017
Export and Import Approvals for Clinical Studies Received
March 23, 2017
Botanix Announces Filing of New Permetrex Product Patents
February 26, 2017
Botanix Announces Expansion of Permetrex License
February 2, 2017
Quarterly Cashflow Report
January 30, 2017
Botanix Announces Positive Human Trial Data
December 6, 2016
Botanix Accelerates Clinical Program with First Human Study
November 10, 2016
DEA Scheduling Decision Supports Botanix Approach
August 14, 2016
Botanix Secures Commercial-Scale Synthetic Cannabidiol
July 28, 2016
Reinstatement to Official Quotation - 15 July 2016
July 13, 2016
Suspension
June 13, 2016
Prospectus - Botanix Pharmaceuticals
May 13, 2016
Human Clinical Study for an Oral Treatment for Osteoporosis
March 30, 2016
Acquisition of Botanix Pharmaceuticals Inc
March 20, 2016
Termination of Agreement to acquire Takor
February 11, 2016
Takor Update - Mappt Update & Collaboration Opportunities
February 10, 2016